Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 4,769 Shares of Stock

Posted by Francis Steltz on Nov 5th, 2026

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) CFO Hans van Houte sold 4,769 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total value of $74,539.47. Following the sale, the chief financial officer directly owned 42,745 shares in the company, valued at $668,104.35. This trade represents a 10.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

On Friday, October 30th, Hans van Houte sold 2,834 shares of Nurix Therapeutics stock. The stock was sold at an average price of $26.28, for a total value of $74,477.52.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $15.95 on Thursday. Nurix Therapeutics, Inc. has a 1-year low of $11.67 and a 1-year high of $28.23. The company has a market capitalization of $1.74 billion, a P/E ratio of 6.90 and a beta of 1.80. The business has a 50 day moving average price of $24.73 and a 200 day moving average price of $20.25.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. On average, research analysts expect that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the subject of several research reports. Royal Bank Of Canada cut their price target on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, October 13th. Wall Street Zen raised shares of Nurix Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, October 15th. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Mizuho lifted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Fourteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.43.

View Our Latest Analysis on Nurix Therapeutics

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

Neutral Sentiment: Wells Fargo lowered its price target for NRIX from $25 to $20 but maintained an “overweight” rating, signaling continued optimism despite reduced expectations. Wells Fargo price target
Neutral Sentiment: CFO Hans van Houte sold 4,769 shares under a pre-arranged Rule 10b5-1 plan. The planned sale may draw attention, though it is less indicative of a new view on the company than an unplanned transaction. SEC filing
Negative Sentiment: Sanofi is discontinuing its Phase 1 trial and terminating the program for SAR448272, an oral STAT6 degrader licensed from Nurix. Losing a partnered clinical program weakens the pipeline’s potential value and appears to be the main catalyst behind the selloff. BioSpace reported the decision was not related to the drug’s target, which may help distinguish the setback from a broader issue with STAT6. Nurix announcement BioSpace report

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds have recently bought and sold shares of NRIX. GAMMA Investing LLC increased its position in Nurix Therapeutics by 95.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after purchasing an additional 620 shares in the last quarter. Nykredit A S acquired a new position in Nurix Therapeutics in the 2nd quarter valued at about $32,000. Integrated Wealth Concepts LLC acquired a new position in Nurix Therapeutics in the 2nd quarter valued at about $33,000. KBC Group NV purchased a new position in Nurix Therapeutics in the 1st quarter valued at about $34,000. Finally, Avalon Trust Co purchased a new position in Nurix Therapeutics in the 2nd quarter valued at about $64,000.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.